CARLA ROMAGNOLLI QUINTINO
Projetos de Pesquisa
Unidades Organizacionais
SCPACEX-62, Hospital Universitário
LIM/20 - Laboratório de Terapêutica Experimental, Hospital das Clínicas, Faculdade de Medicina
LIM/20 - Laboratório de Terapêutica Experimental, Hospital das Clínicas, Faculdade de Medicina
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
- Cerebrovascular risk factors and their time-dependent effects on stroke survival in the EMMA cohort study(2023) GOULART, A. C.; VARELLA, A. C.; TUNES, G.; ALENCAR, A. P.; SANTOS, I. S.; ROMAGNOLLI, C.; GOODEN, T. E.; THOMAS, G. N.; LIP, G. Y. H.; OLMOS, R. D.; LOTUFO, P. A.; BENSENOR, I. M.To investigate the time-dependent effects of traditional risk factors on functional disability in all-cause mortality post-stroke, we evaluated data from a long-term stroke cohort. Baseline cerebrovascular risk factors (CVRF) and functionality at 1 and 6 months were evaluated in survivors from a prospective stroke cohort using the modified Rankin scale (m-RS), which classifies participants as improvement of disability, unchanged disability (at least moderate), and worsening disability. Cox regression models considering baseline risk factors, medication use, and functionality 6 months after stroke were fitted to identify their time-dependent effects up to 12 years of follow-up. Adjusted hazard ratios (HR) with 95% confidence intervals (CI) are presented. Among 632 survivors (median age 68, 54% male, 71% first-ever episode), age and functional disability (unchanged and worsening) 6 months after ischemic stroke had time-dependent effects on all-cause mortality risk up to 12 years of follow-up. The most impacting risk factors were unchanged (at least moderate) (HR, 2.99; 95%CI: 1.98-4.52) and worsening disability (HR, 2.85; 95%CI: 1.26-6.44), particularly in the first two years after a stroke event (Time 1: >= 6 mo to <2.5 y). Worsening disability also impacted mortality in the period from >= 2.5 to <7.5 years (Time 2) of follow-up (HR, 2.43 (95%CI: 1.03-5.73). Other baseline factors had a fixed high-risk effect on mortality during follow-up. Post-stroke and continuous medication use had a fixed protective effect on mortality. Functional disability was the main contributor with differential risks of mortality up to 12 years of follow-up.
- Cardiovascular medications and long-term mortality among stroke survivors in the Brazilian Study of Stroke Mortality and Morbidity (EMMA)(2022) SOUZA, Karla A. S.; VARELLA, Ana C.; OLMOS, Rodrigo D.; ROMAGNOLLI, Carla; GOODEN, Tiffany E.; THOMAS, G. Neil; LIP, Gregory Y. H.; SANTOS, Itamar S.; LOTUFO, Paulo A.; BENSENOR, Isabela M.; GOULART, Alessandra C.Aim To investigate the association between medication use and long-term all-cause mortality in a Brazilian stroke cohort. Methods Both ischemic and hemorrhagic stroke were evaluated. Medication use was assessed as: never, only pre-stroke, only post-stroke, and continuous use. We evaluated anti-hypertensives, anti-diabetics, lipid-lowering drugs, anti-platelets, and anti-coagulants. Cox regression models were adjusted for sociodemographic and cardiovascular risk factors. Results Among 1173 incident stroke cases (median age: 68; 86.8% were ischemic, 70% first-ever stroke), medication use was low (overall: 17.5% pre-stroke, 26.4% post-stroke, and 40% were under continuous use). Anti-hypertensives and anti-platelets (aspirin) were the continuous cardiovascular medications used most often, at 83.5% and 72%, respectively, while statins (39.7%) and anti-diabetics (31.3%) were the least used. Medication use (pre-stroke, post-stroke and continuous use) was associated with a reduction in all-cause mortality risk, particularly among those under continuous use (multivariable hazard ratio, 0.52; 95% confidence interval (CI), 0.46-0.66) compared with never-users. Among ischemic stroke patients, this effect was similar (multivariable hazard ratio, 0.52; 95% CI, 0.40-0.68). No significant associations were evident among hemorrhagic stroke patients. Conclusions The risk of all-cause mortality was reduced by 48% among those with ischemic stroke under continuous use of medications. Secondary prevention should be emphasized more strongly in clinical practice. Geriatr Gerontol Int 2022; center dot center dot: center dot center dot-center dot center dot.
- Patient and Public Involvement and Engagement (PPIE): first steps in the process of the engagement in research projects in Brazil(2022) BENSENOR, I. M.; GOULART, A. C.; THOMAS, G. N.; LIP, G. Y. H.; ARASALINGAM, Ajini; BEANE, Abi; BENSENOR, Isabela M.; BROCKLEHURST, Peter; CHENG, Kar Keung; EL-BOURI, Wahbi; FENG, Mei; GREENFIELD, Sheila; GUO, Yutao; GURUPARAN, Mahesan; GUSSO, Gustavo; GOODEN, Tiffany E.; HANIFFA, Rashan; HUMPHREYS, Lindsey; JOLLY, Kate; JOWETT, Sue; KODIPPILY, Chamira; KUMARENDRAN, Balachandran; LANCASHIRE, Emma; LANE, Deirdre A.; LI, Xuewen; LIP, Gregory Y. H.; LI, Yan-guang; LOBBAN, Trudie; LOTUFO, Paulo A.; MANASEKI-HOLLAND, Semira; MOORE, David; NIRANTHARAKUMAR, Krishnarajah; OLMOS, Rodrigo D.; PASCHOAL, Elisabete; PIRASANTH, Paskaran; POWSIGA, Uruthirakumar; ROMAGNOLLI, Carla; SANTOS, Itamar S.; SHANTSILA, Alena; SHERON, Vethanayagan Antony; SHRIBAVAN, Kanesamoorthy; SZMIGIN, Isabelle; SUBASCHANDREN, Kumaran; SURENTHIRAKUMARAN, Rajendra; TAI, Meihui; THAVARAJAH, Bamini; THOMAS, G. Neil; TOIPPA, Timo; VARELLA, Ana C.; WANG, Hao; WANG, Jingya; ZHANG, Hui; ZHONG, JiaoyuePatient and Public Involvement and Engagement (PPIE) - sometimes called Community Engagement and Involvement (CEI) - comes as a big challenge but one that can be very helpful for health care professionals and stakeholders in planning better health policies for attending to the main needs of the community. PPIE involves three pillars: public involvement, public engagement, and participation. Public involvement occurs when members of the general population are actively involved in developing the research question, designing, and conducting the research. Public engagement tells people about new studies, why they are important, the impact of results, the possible implication of the main findings for the community, and the possible impact of these new findings in society, as well as, in the dissemination of knowledge to the general population. Participation is being a volunteer in the study. Our experience with PPIE, to the best of our knowledge the first initiative in Brazil, is a partnership with the University of Birmingham, the University of Liverpool, and the NIHR Global Health Group on Atrial Fibrillation (AF) Management focusing on the AF care pathway exploring the important aspects of diagnosis and treatment in the primary care system from a low-middle income area in Sao Paulo. The involvement of patients/public in the research represents a new step in the process of inclusion of all segments of our society based on patient illness and the gaps in knowledge aiming to open new horizons for continuous improvement and better acceptance of research projects.